SAILIFE

Sai Life Sciences Limited

Integrated CRDMO for global pharma and biotech — research through manufacturing

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

sailife.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹1389.40
Market cap
29,428 Cr
Stock P/E
81.4
P/B
11.85
ROE (FY26)
14.0%
ROCE (FY26)
19.6%
Operating margin (FY26)
21.2%
Debt / equity (FY26)
0.04
OCF / EBITDA (FY26)
80.7%
OCF / EBITDA (3Y)
82.1%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Sai Life Sciences is an Indian drug research and manufacturing services company that supports pharma and biotech customers across the life of a drug, from early discovery to late-stage and commercial manufacturing, through contract research (CRO) and development and manufacturing (CDMO) businesses.

Company snapshot

22ndBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Net margin of 15.9% — the business keeps a healthy share of every rupee it earns.
2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricDec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales440 Cr580 Cr496 Cr537 Cr556 Cr602 Cr554 Cr
Operating expenses (approx.)320 Cr422 Cr375 Cr392 Cr369 Cr426 Cr406 Cr
EBITDA120 Cr158 Cr121 Cr146 Cr188 Cr177 Cr148 Cr
OPM %27.2%27.2%24.4%27.1%33.8%29.3%26.7%
Other income9 Cr10 Cr10 Cr15 Cr8 Cr16 Cr4 Cr
Interest23 Cr11 Cr12 Cr9 Cr10 Cr8 Cr8 Cr
Depreciation34 Cr37 Cr38 Cr40 Cr44 Cr45 Cr46 Cr
Profit before tax72 Cr119 Cr81 Cr112 Cr134 Cr139 Cr98 Cr
Tax %24.8%25.7%25.1%25.2%25.2%25.1%25.2%
Net profit54 Cr88 Cr60 Cr84 Cr100 Cr104 Cr73 Cr
EPS (₹)₹2.89₹4.24₹2.90₹4.01₹4.77₹4.93₹3.46

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales870 Cr1,217 Cr1,465 Cr1,695 Cr2,192 CrSign in free for the trailing twelve months
Operating expenses (approx.)748 Cr1,052 Cr1,180 Cr1,289 Cr1,561 CrSign in free for the trailing twelve months
EBITDA121 Cr165 Cr285 Cr406 Cr631 CrSign in free for the trailing twelve months
OPM %13.9%13.6%19.5%23.9%28.8%Sign in free for the trailing twelve months
Other income28 Cr28 Cr29 Cr37 Cr49 CrSign in free for the trailing twelve months
Interest50 Cr77 Cr86 Cr76 Cr39 CrSign in free for the trailing twelve months
Depreciation90 Cr99 Cr119 Cr139 Cr167 CrSign in free for the trailing twelve months
Profit before tax10 Cr16 Cr109 Cr228 Cr466 CrSign in free for the trailing twelve months
Tax %35.8%39.1%24.2%25.3%25.2%Sign in free for the trailing twelve months
Net profit6 Cr10 Cr83 Cr170 Cr349 CrSign in free for the trailing twelve months
EPS (₹)₹0.35₹0.55₹4.57₹8.83₹16.63Sign in free for the trailing twelve months
Dividend payout %———0.0%0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital18 Cr18 Cr18 Cr21 Cr21 Cr
Reserves861 Cr870 Cr957 Cr2,108 Cr2,463 Cr
Borrowings751 Cr699 Cr710 Cr129 Cr95 Cr
Other liabilities534 Cr599 Cr590 Cr903 Cr1,047 Cr
Total liabilities2,164 Cr2,187 Cr2,275 Cr3,160 Cr3,626 Cr
Fixed assets (net)743 Cr778 Cr926 Cr1,477 Cr1,809 Cr
CWIP189 Cr151 Cr107 Cr124 Cr270 Cr
Investments0.02 Cr2 Cr2 Cr2 Cr51 Cr
Inventories127 Cr140 Cr87 Cr119 Cr151 Cr
Trade receivables243 Cr284 Cr256 Cr355 Cr374 Cr
Cash & bank116 Cr70 Cr24 Cr91 Cr82 Cr
Other assets747 Cr763 Cr873 Cr991 Cr890 Cr
Total assets2,164 Cr2,187 Cr2,275 Cr3,160 Cr3,626 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity105 Cr219 Cr263 Cr314 Cr509 Cr
Cash from investing-104 Cr-102 Cr-192 Cr-537 Cr-395 Cr
Cash from financing72 Cr-201 Cr-95 Cr301 Cr-124 Cr
Net cash flow73 Cr-83 Cr-25 Cr79 Cr-9 Cr
Free cash flow (OCF − Capex)-4 Cr148 Cr82 Cr-55 Cr-84 Cr

Ratios

MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %3.6%5.9%11.6%13.5%19.6%
ROE %0.7%1.1%8.5%8.0%14.0%
Debtor days10285647662
Inventory days171119759495
Days payable269178172255180
Cash conversion cycle426-33-85-23
OCF / EBITDA %86.5%133.0%92.2%77.4%80.7%
OCF / EBITDA % (3 years)——102.7%93.0%82.1%
Debt / equity0.860.790.730.060.04
Current ratio1.321.271.282.051.69
Net debt / EBITDA5.243.822.400.090.02